Transcription elongation factor SPT5–RNA polymerase II complex (SPT5–Pol II complex)

The SPT5–RNA polymerase II complex is a fundamental regulatory unit in eukaryotic gene expression, primarily responsible for controlling the processivity and speed of transcription elongation (Bernecky et al., 2017, Nature). SPT5 (encoded by the SUPT5H gene) is a highly conserved transcription factor that binds the RNA polymerase II (Pol II) "clamp" and "protrusion" domains to stabilize the transcription bubble and prevent premature dissociation (UniProt P41091). This complex plays a dual role: it initially facilitates promoter-proximal pausing of Pol II, a critical checkpoint for mRNA capping, and subsequently transitions into a positive elongation factor upon phosphorylation by the Positive Transcription Elongation Factor b (P-TEFb/CDK9) (Yamaguchi et al., 1999, Genes Dev). In many cancers, particularly those driven by the MYC oncogene, this complex is hijacked to maintain high levels of transcriptional output, making it an attractive therapeutic target (Bradner et al., 2017, Cell). Viral pathogens, most notably HIV-1, also utilize the SPT5–Pol II complex to ensure efficient transcription of the viral genome via the Tat protein (Kim et al., 2002, Mol Cell Biol). Current pharmacological strategies focus on inhibiting the kinases that regulate this complex, such as CDK9 and CDK7, though research into direct disruptors of the SPT5-Pol II interface is ongoing (Kwiatkowski et al., 2014, Nature). Targeting this complex allows for the selective suppression of highly transcribed genes, which are often those required for cancer cell survival and viral replication. However, the essential nature of transcription elongation in all cells presents a significant challenge for achieving a therapeutic window without systemic toxicity.

Other names

SUPT5H–RNA polymerase II complexDSIF–RNA polymerase II complexSPT5–RNAPII complexSuppressor of Typtophan 5 Homolog–RNA polymerase II complex

Inhibition of transcription elongation by preventing the transition of RNA polymerase II from a paused state to productive elongation, typically via inhibition of regulatory kinases like CDK9 or CDK7 (Bradner et al., 2017, Cell).